Loading patent…
AssigneePfizer Inc.
InventorsAnne Barbara Cropp, Albert Kim, David Raymond Plowchalk, Kevin Richard Sweeney, Ellen Qiao Wang
Estimating the term…
The present invention relates to therapeutic dosing regimens utilizing a dose reduction strategy for treating disorders characterized by marked elevations of low density protein cholesterol (LDL-C) in the plasma of a patient. The subject therapeutic dosing regimens involve delivering as a single administration or plurality of administrations of an anti-proprotein convertase subtilisin kexin type 9 (PCSK9) antagonist antibody as an initial dose of at least about 100 mg, and delivering as a single administration or plurality of administrations at a subsequent dose in an amount that is about the same as the initial dose, or at least half the initial dose after the patient has a LDL-C level at or below about 25, 20, 15 or 10 mg/dL, preferably at or below 10 mg/dL.
A method for treating a patient diagnosed with a disorder characterized by an elevated low-density lipoprotein cholesterol (LDL-C) level in the blood, comprising delivering to the patient as a single administration or plurality of administrations an initial dose of at least about 100 mg of a proprotein convertase subtilisin kexin type 9 (PCSK9) antagonist antibody, and delivering to the patient a single administration or plurality of administrations at a subsequent dose that is about the same as the initial dose, or at least half the initial dose after the patient has a LDL-C level at or below about 25, 20, 15 or 10 mg/dL, wherein all administrations are separated in time from each other by at least about two weeks.
Dependencies are inferred from the claim text.